Moxifloxacin Hydrochloride (400 mg tablet)

Moxifloxacin is an oral broad‐spectrum fluoroquinolone antibiotic used to treat various bacterial infections. Each film-coated tablet contains 400 mg moxifloxacin (as moxifloxacin HCl). It is often sold under brand names such as Avelox, but is also available generically. Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and cell division, thus exerting a bactericidal effect.

Indications

Moxifloxacin is indicated in adults (≥18 years) for infections caused by susceptible bacteria, including:

• Respiratory tract infections: Community-acquired pneumonia; acute bacterial sinusitis.
• Chronic bronchitis exacerbations: Acute bacterial exacerbation of chronic bronchitis.
• Skin/Soft tissue infections: Uncomplicated and complicated skin and skin structure infections.
• Intra-abdominal infections: Complicated intra-abdominal infections (often given with metronidazole).
• Other: Plague (Yersinia pestis infection) – a rare indication.

Moxifloxacin should be reserved for proven or strongly suspected infections due to susceptible organisms. Because of resistance concerns, it is generally avoided for mild infections or used only when alternatives are not appropriate (e.g. when first-line antibiotics cannot be used). It is not effective against viral infections.

Dosage and Administration

• Usual dose: 400 mg taken once daily by mouth.
• Duration: Depends on the type of infection (typically 5–21 days). For example, 7–14 days for pneumonia, 5–10 days for bronchitis, ~10 days for sinusitis, 7–21 days for complicated skin infections. Always follow the duration prescribed by the physician.
• Administration: Swallow tablets whole with a full glass of water. Moxifloxacin may be taken with or without food; patients should drink plenty of fluids during therapy. Do not chew or crush the tablet.
• Missed dose: If you miss a dose and it’s at least 8 hours before your next scheduled dose, take it as soon as remembered. Do not double-up doses on the next day.
• Special populations: No dose adjustment is required for mild-to-moderate renal or hepatic impairment. (Severe renal impairment hasn’t been shown to significantly alter moxifloxacin levels, and standard dosing is usually used.)

Contraindications

• Known hypersensitivity to moxifloxacin or other fluoroquinolones (e.g. ciprofloxacin, levofloxacin).
• History of tendon disorders (e.g. ruptures) related to fluoroquinolone use.
• Intra-arterial administration (irritation in vessels): Moxifloxacin tablets are for oral use only.

Warnings and Precautions

Boxed Warnings (FDA): Fluoroquinolones, including moxifloxacin, carry a boxed warning for disabling and potentially irreversible reactions. These serious adverse effects include:

• Tendinitis and tendon rupture: Risk is higher in the elderly (>60 years), transplant recipients, or patients on corticosteroids. Tendon rupture can occur during or after therapy. Discontinue moxifloxacin immediately if tendon pain or swelling occurs, and avoid exercise of the affected area.
• Peripheral neuropathy: Moxifloxacin may cause severe, potentially irreversible peripheral neuropathy (tingling, numbness, pain, weakness). This can occur even after a short treatment course. If neuropathic symptoms develop, stop the drug.
• Central nervous system (CNS) effects: Dizziness, confusion, tremor, and seizures have been reported. Use caution in patients with known seizure disorders.
• Exacerbation of myasthenia gravis: Fluoroquinolones can worsen muscle weakness in patients with myasthenia gravis; moxifloxacin should be avoided in these patients.

Other important warnings:

• QT interval prolongation: Moxifloxacin can prolong the QT interval, potentially causing torsade de pointes or other arrhythmias. Avoid in patients with known QT prolongation, clinically significant bradycardia, or those on class I or III antiarrhythmic drugs. Correct electrolyte imbalances (hypokalemia, hypomagnesemia) before use.
• Hypersensitivity reactions: Serious (sometimes fatal) allergic reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, have occurred. Discontinue at the first sign of a rash or other allergic symptom.
• Clostridioides difficile–associated diarrhea (CDAD): Antibiotic-associated colitis has occurred; evaluate if patient develops severe diarrhea.
• Hepatotoxicity: Rare cases of liver injury (hepatitis, hepatic failure) have been reported Advise patients to report symptoms such as yellowing of skin/eyes, dark urine, severe abdominal pain, or unexplained fatigue.
• Hyperglycemia/Hypoglycemia: Fluoroquinolones can cause disturbances in blood glucose, particularly in diabetics. Monitor blood sugar in diabetic patients.
• Photosensitivity: Moxifloxacin can cause photosensitivity/phototoxicity. Patients should minimize sun or UV exposure (use sunscreen, cover skin) while on treatment.
• Musculoskeletal: In juvenile animals, moxifloxacin causes arthropathy. It is not approved for use in children (<18 years) due to risk of joint/bone damage.

Adverse Reactions

Common (≥2–3% of patients): Nausea, diarrhea, headache, dizziness. Others include vomiting, abdominal pain, and insomnia.

Less common / serious: Tendon disorders, peripheral neuropathy, seizures, serious skin reactions (rash, photosensitivity, SJS), liver enzyme elevations, Clostridioides difficile colitis, and QT prolongation have been reported. Hematologic abnormalities (anemia, low platelets, leukopenia) and allergic reactions (anaphylaxis) are rare. If any severe reactions occur, the drug should be stopped and medical attention sought.

Drug Interactions

• Multivalent cations: Antacids containing magnesium or aluminum, sucralfate, iron supplements, or multivitamins (with zinc or iron) can chelate moxifloxacin and greatly reduce its absorption. Advice: Take moxifloxacin at least 4 hours before or 8 hours after these products.
• Warfarin and other anticoagulants: Moxifloxacin may enhance the anticoagulant effect. Monitor the INR/prothrombin time and watch for bleeding if patients are on warfarin or similar drugs.
• Antiarrhythmics (Class I/III): Concurrent use with drugs like amiodarone, sotalol, quinidine is not recommended due to additive QT-prolongation risk.
• Oral hypoglycemics/insulin: Monitor blood glucose when used with moxifloxacin, as fluoroquinolones can cause hypoglycemia or hyperglycemia.
• Others: Although moxifloxacin is not extensively metabolized by cytochrome P450 enzymes, remain cautious of any drug affecting gastric pH or QT prolonging agents. Digoxin absorption is unaffected; no dose adjust is needed.

Use in Special Populations

• Pregnancy: Animal studies suggest potential fetal harm; use only if the benefit justifies the risk.
• Breastfeeding: It is not known if moxifloxacin is excreted in human milk. Advise caution or avoid use while nursing.
• Pediatrics: Contraindicated in children and adolescents (<18 years) due to effects on cartilage development. No safety/efficacy data in pediatric patients.
• Geriatrics: Patients ≥65 years have higher risk of tendon rupture and CNS effects with fluoroquinolones. Use caution, especially if taking corticosteroids. Also watch for QT prolongation susceptibility.
• Renal/Hepatic impairment: As noted, no dose adjustment is generally required (moxifloxacin is eliminated mainly unchanged).

Mechanism of Action

Moxifloxacin is a synthetic fluoroquinolone. Its bactericidal action stems from inhibition of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV). By blocking these enzymes, moxifloxacin prevents DNA supercoiling and replication in susceptible bacteria. Because this mechanism differs from β-lactams and macrolides, many organisms resistant to those drugs may still be susceptible to moxifloxacin. However, resistance can develop via mutations in the target enzymes or efflux mechanisms, so misuse should be avoided.

Patient Counseling

Patients should be instructed to take moxifloxacin exactly as prescribed (once daily, at the same time each day). Tablets should be swallowed whole, with or without food, and ample fluids should be consumed. Advise patients not to skip doses or stop early – they must complete the full course even if they feel better, to prevent relapse or resistance. Instruct patients on the risk of tendon pain or swelling and to report it immediately. Warn about light sensitivity and urge use of sun protection. Remind patients to inform their doctor or pharmacist about all other medications to avoid interactions, and to notify their healthcare provider if they experience any severe side effects (e.g. rash, jaundice, irregular heartbeat, seizures).